Pivotal study for PSD502 -- the first potential treatment for pr...

Courtesy EurekAlert! - Chemistry, Physics and Materials Sciences  Wed, 11/18/2009 - 23:00

(HealthStar PR) Results of the double-blind treatment phase of this study, which enrolled patients from the U.S., Canada and Poland, are consistent with previously reported results of the pivotal trial conducted in Europe and showed that men who were treated with PSD502 five minutes before intercourse were able to delay ejaculation up to five times longer than those who used placebo.

Additionally, patients and partners in both trials reported significant improvements in sexual satisfaction, and the drug was well tolerated.

Tags:

 

More related items

Clinicians Override Most Electronic Medication Safety...
A new study reveals that clinicians using electronic prescribing often override the alerts and rely instead on their own judgment. The study suggests that most clinicians find the current...

Science in the News - Friday 30 January 2009
Patients suffering from the early stages of multiple sclerosis have shown significant improvements in their condition after being injected with stem cells, scientists say.

Teaming with Microbes: A Gardener's Guide to the Soil...
Smart gardeners know that soil is anything but an inert substance. Healthy soil is teeming with life-not just earthworms and insects, but a staggering multitude of bacteria, fungi, and other...

Biomaterials Science, Second Edition: An Introduction...
The second edition of this bestselling title provides the most up-to-date comprehensive review of all aspects of biomaterials science by providing a balanced, insightful approach to learning...


 

Post new comment

The content of this field is kept private and will not be shown publicly.
science-nature.marc8.com